
| Disease Domain | Count |
|---|---|
| Neoplasms | 5 |
| Nervous System Diseases | 2 |
| Immune System Diseases | 1 |
| Infectious Diseases | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 6 |
Target- |
Mechanism Mitochondrial oxidative phosphorylation uncouplers |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism GABA receptor antagonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Top II modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date25 Aug 2025 |
Sponsor / Collaborator |
Start Date05 Jun 2025 |
Sponsor / Collaborator |
Start Date01 Jun 2025 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Erucic acid ( GABA receptor x NF-κB x caspase 3 ) | Seizures More | Preclinical |
Niclosamide | Pseudomonas aeruginosa infection More | Preclinical |
Chrysomycin A ( Top II ) | Neoplasms More | Preclinical |
3b(Jouf University) ( PIM1 ) | Neoplasms More | Preclinical |
3a(Jouf University) ( PIM1 ) | Neoplasms More | Preclinical |





